PharmaMar to Present at the Stifel 2017 Healthcare Conference

Tuesday, November 14, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MADRID, November 14, 2017 /PRNewswire/ --

PharmaMar (MCE: PHM) will present and meet institutional investors in on

one meetings at the Stifel Nicolaus Weisel Healthcare Conference on November 15th in New York City. The presentation will take place on Wednesday November 15th
at 2:00pm ET at the New York Lotte Palace. Presenting for PharmaMar will be José María Fernández, Ph.D., Chief Executive Officer and Chairman of the Board.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

To access a live audio webcast of the presentation, please visit http://wsw.com/webcast/stifel10/Pharma Mar/

A webcast replay will be available on the PharmaMar website for 90 days following the call by visiting the same link http://wsw.com/webcast/stifel10/Pharma Mar/

About PharmaMar  

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)

SOURCE PharmaMar



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store